Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation

Table 2

Selected studies on the treatment of EBV infection or EBV-related posttransplant lymphoproliferation with adoptively transferred EBV-specific T cells.

Authors	Number of patients	Indication for EBV-CTL	EBV-CTL donor	EBV-CTL preparation*	Number of doses	Total number EBV-CTLs infused	Response in PTLD patients	Complications**	Reference
Gustafsson et al. (2000)	6	rising EBV load after HSCT	HSCT-donor	Expansion	2–4	2×10^7/m² to 4×10^7/m²	NA		[126]
Haque et al. (2002)	8	PTLD after SOT or HSCT	Third-party	Expansion	1–6	1×10^6/kg to 6×10^6/kg	3/8 CR; 1/8 PR		[90]
Sun et al. (2002)	2	2 PTLD after SOT	Third-party	Expansion	3	1.5×10^7/kg	2/2 CR		[127]
Comoli et al. (2007)	4	1 rising EBV load; 3 PTLD after HSCT	HSCT donor	Expansion	2–4	1.5×10^6/kg to 5.5×10^6/kg	3/3 CR		[119]
Gandhi et al. (2007)	3	PTLD after SOT	Third party	Expansion	2–8	2×10^6/kg to 16×10^6/kg	2/3 CR		[128]
Haque et al. (2007)	33	PTLD after SOT or HSCT	Third-party	Expansion	4	8×10^6/kg	14/33 CR; 3/33 PR	De novo alloantibodies in 1/33 pts	[89]
Barker et al. (2010)	2	PTLD after CBT	Third-party	Expansion	5-6	5×10^6/kg to 6×10^6/kg	2/2 CR		[129]
Heslop et al. (2010)	114	101 prevention and 13 treatment of PTLD after HSCT	HSCT-donor	Expansion	1–3	2×10^7/m² to 5×10^7/m²	11/13 CR; no PTLD in the prevention group	Swelling at side of disease	[130]
Moosmann et al. (2010)	6	PTLD after HSCT	HSCT-donor	Caption	1	0.3×10^6 to 7.4×10^6 (abs.)	3/6 CR		[94]
Uhlin et al. (2012)	1	PTLD after CBT	Haploidentical, third-party donor	Caption	1	1.1×10^4/kg	1/1 CR		[93]
Doubrovina et al. (2012)***	19	PTLD after HSCT	14 HSCT-donor; 5 third party	Expansion	3	3×10^6/kg	13/19 CR		[131]
Icheva et al. (2013)	10	2 EBV reactivation; 8 PTLD after HSCT	HSCT-donor	Caption	1-2	1.5×10^2/kg to 5.4×10^4/kg	6/8 CR	Skin-GvHD I-II° in 1/10 pts	[95]

∗Expansion: EBV-CTLs were expanded in vitro using repetitive stimulation with autologous, EBV-transformed B cells (lymphoblastoid cell lines (LCL); Caption: EBV-specific T cells were labeled with magnetic beads and isolated via a magnetic column without ex vivo expansion; **restricted to reported CTL-related complications; in regard to GvHD, only de novo GvHD is reported; ***restricted to patients receiving manipulated EBV-CTLs.
CBT: cord blood transplantation; CR: complete remission; EBV-CTL: EBV-specific cytotoxic T-lymphocytes; HSCT: hematopoietic stem cell transplantation; GvHD: graft-versus-host disease; NA: not available; PR: partial response; PTLD: posttransplant lymphoproliferative disease; Pts: patients; SOT: solid organ transplantation.